Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

Maurizio Zangari; Dixie Esseltine; Choon Kee Lee; Bart Barlogie; Francesca Elice; Michael J. Burns; Seung Hee Kang; Shmuel Yaccoby; Kevin Najarian; Paul Richardson; Peter Sonneveld; Guido Tricot

doi:10.1111/j.1365-2141.2005.05733.x

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

Maurizio Zangari
, Dixie Esseltine
, Choon Kee Lee
, Bart Barlogie
, Francesca Elice
, Michael J. Burns
, Seung Hee Kang
, Shmuel Yaccoby
, Kevin Najarian
, Paul Richardson
, Peter Sonneveld
, Guido Tricot

Research output: Contribution to journal › Article › peer-review

182 Scopus citations

Abstract

The prompt response to bortezomib observed in a 63-year-old woman with multiple myeloma was associated with a significant increase in alkaline phosphatase (ALP). After similar elevations were noted in patients responding to bortezomib, thalidomide, dexamethasone combination, ALP levels were analysed in two large bortezomib trials. A statistically significant elevation of ALP from baseline was observed in responding patients (complete and partial responders) within three cycles of therapy. The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation.

Original language	English
Pages (from-to)	71-73
Number of pages	3
Journal	British Journal of Haematology
Volume	131
Issue number	1
DOIs	https://doi.org/10.1111/j.1365-2141.2005.05733.x
State	Published - Oct 2005
Externally published	Yes

Keywords

Bone
Bortezomib
Intact parathyroid hormone
Myeloma
Osteoblast

Access to Document

10.1111/j.1365-2141.2005.05733.x

Cite this

@article{fd1c9484e2fd42e78f76f4cc3c6286b5,

title = "Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma",

abstract = "The prompt response to bortezomib observed in a 63-year-old woman with multiple myeloma was associated with a significant increase in alkaline phosphatase (ALP). After similar elevations were noted in patients responding to bortezomib, thalidomide, dexamethasone combination, ALP levels were analysed in two large bortezomib trials. A statistically significant elevation of ALP from baseline was observed in responding patients (complete and partial responders) within three cycles of therapy. The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation.",

keywords = "Bone, Bortezomib, Intact parathyroid hormone, Myeloma, Osteoblast",

author = "Maurizio Zangari and Dixie Esseltine and Lee, \{Choon Kee\} and Bart Barlogie and Francesca Elice and Burns, \{Michael J.\} and Kang, \{Seung Hee\} and Shmuel Yaccoby and Kevin Najarian and Paul Richardson and Peter Sonneveld and Guido Tricot",

year = "2005",

month = oct,

doi = "10.1111/j.1365-2141.2005.05733.x",

language = "English",

volume = "131",

pages = "71--73",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

AU - Zangari, Maurizio

AU - Esseltine, Dixie

AU - Lee, Choon Kee

AU - Barlogie, Bart

AU - Elice, Francesca

AU - Burns, Michael J.

AU - Kang, Seung Hee

AU - Yaccoby, Shmuel

AU - Najarian, Kevin

AU - Richardson, Paul

AU - Sonneveld, Peter

AU - Tricot, Guido

PY - 2005/10

Y1 - 2005/10

N2 - The prompt response to bortezomib observed in a 63-year-old woman with multiple myeloma was associated with a significant increase in alkaline phosphatase (ALP). After similar elevations were noted in patients responding to bortezomib, thalidomide, dexamethasone combination, ALP levels were analysed in two large bortezomib trials. A statistically significant elevation of ALP from baseline was observed in responding patients (complete and partial responders) within three cycles of therapy. The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation.

AB - The prompt response to bortezomib observed in a 63-year-old woman with multiple myeloma was associated with a significant increase in alkaline phosphatase (ALP). After similar elevations were noted in patients responding to bortezomib, thalidomide, dexamethasone combination, ALP levels were analysed in two large bortezomib trials. A statistically significant elevation of ALP from baseline was observed in responding patients (complete and partial responders) within three cycles of therapy. The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation.

KW - Bone

KW - Bortezomib

KW - Intact parathyroid hormone

KW - Myeloma

KW - Osteoblast

UR - https://www.scopus.com/pages/publications/27744557499

U2 - 10.1111/j.1365-2141.2005.05733.x

DO - 10.1111/j.1365-2141.2005.05733.x

M3 - Article

C2 - 16173965

AN - SCOPUS:27744557499

SN - 0007-1048

VL - 131

SP - 71

EP - 73

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

Abstract

Keywords

Access to Document

Fingerprint

Cite this